Moxaverine

DB12251InvestigationalSmall molecule

Moxaverine has been investigated for the treatment of Retina, Ocular Physiology, and Regional Blood Flow.

Chemical structure of Moxaverine
Formula / weight
C20H21NO2 · 307.393 g/mol (avg)

Resolves to

Compound
UNIIP3P08Y1XJ4CAS10539-19-2ChEMBLCHEMBL2105060ChEBI135307PubChem70882
Clinical / RWD
RxNorm52918ATCA03AD30
Structure
InChIKeyMYCMTMIGRXJNSO-UHFFFAOYSA-NSMILESCCC1=NC(CC2=CC=CC=C2)=C2C=C(OC)C(OC)=CC2=C1

What you can answer from here — as of August 30, 2026

4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in

Which companies are running trials of Moxaverine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In